Oramed Pharmaceuticals, Inc (NASDAQ:ORMP) To Announce Phase-2 Results


Dallas, Texas 01/29/2014 (FINANCIALSTRENDS) – Oramed Pharmaceuticals, Inc (NASDAQ:ORMP), a developer of various oral drug -delivery systems said  that it will announce results of the company’s Phase-2a clinical-trial for its ORMD-0801 oral insulin-capsule for treating Type 2 diabetes on 30 January 2014. Nadav Kidron, the Oramed Pharmaceuticals, Inc (NASDAQ:ORMP) Chief Executive officer will present these findings at an investor-conference that is slated to take place at Tel Aviv, Israel’ Tel Aviv Stock Exchange. This Phase 2a trial was conducted in the U.S. under FDA approval. It was designed specifically to show the overall safety-profile of the drug. Thirty patients suffering from Type 2 diabetes participated in the randomized, double-blind trial in an in-patient-setting for 1 week of the treatment.

Oramed Pharmaceuticals, Inc (NASDAQ:ORMP)’s ORMD-0801 is an orally-ingestible insulin capsule used for early stages of type-2 diabetes, when it is still able to slow the degeneration rate of the disease by providing the additional insulin to the body and also by allowing pancreatic-respite. Moreover, the orally-administered insulin also has the potential benefit of an enhanced patient compliance at this very crucial stage. It is also advantageous as it mimics the insulin’s natural-location and the gradients in the body by 1st passing through the liver before it enters the bloodstream.

Oramed Pharmaceuticals, Inc (NASDAQ:ORMP) is a technology-pioneer in the field of oral-delivery solutions for various vaccine and drugs that are currently being delivered via injection. Incorporated  in 2006, Oramed Pharmaceuticals, Inc (NASDAQ:ORMP)’s  Protein Oral Delivery technology is typically based on more than 30 years of research by various top research-scientists at the Hadassah Medical Center in Jerusalem. Oramed Pharmaceuticals, Inc (NASDAQ:ORMP) is seeking to revolutionize diabetes treatment via its proprietary flagship-product, the orally-ingestible insulin capsule ( ORMD-0801 ) which is currently in Phase-2 clinical trials on the patients suffering from type-2 diabetes (T2DM) under an IND application with the United States Food Drug Administration.